{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:21:00Z","timestamp":1778239260410,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["R01 AG034676"],"award-info":[{"award-number":["R01 AG034676"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.amjcard.2019.02.043","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T11:00:33Z","timestamp":1552042833000},"page":"1739-1744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease"],"prefix":"10.1016","volume":"123","author":[{"given":"Alanna M.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan A.","family":"Weston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill M.","family":"Killian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.02.043_bib0001","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0002","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0003","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0004","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0005","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0006","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0007","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.mayocp.2012.08.012","article-title":"History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population","volume":"87","author":"Rocca","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0008","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","article-title":"Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project","volume":"87","author":"St. Sauver","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0009","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/aje\/kwq482","article-title":"Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project","volume":"173","author":"St. Sauver","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0010","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ije\/dys195","article-title":"Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system","volume":"41","author":"St. Sauver","year":"2012","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0011","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mayocp.2013.04.021","article-title":"Age and sex patterns of drug prescribing in a defined American population","volume":"88","author":"Zhong","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0012","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0013","unstructured":"Centers for Medicare and Medicaid Chronic Conditions Data Warehouse (CCW), CCW Condition Algorithms. https:\/\/www.ccwdata.org\/web\/guest\/condition-categories"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0014","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","article-title":"Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context","volume":"20","author":"Toth","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/03007995.2017.1401529","article-title":"Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review","volume":"34","author":"Cherepanov","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0016","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/13696998.2017.1327440","article-title":"Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results","volume":"20","author":"Toth","year":"2017","journal-title":"J Med Econ"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0017","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.02.043_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","article-title":"Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges","volume":"14","author":"Sampson","year":"2012","journal-title":"Curr Atheroscler Rep"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919302887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919302887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:29:24Z","timestamp":1757572164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919302887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0002914919302887"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.02.043","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735472539.793561417","asserted-by":"object"}]},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}